Patient Access Schemes in Homecare
Patient access schemes enable the NHS to provide access to innovative medicines
When accessing new drugs and treatments, the cost of the treatment and the evidence on its effectiveness are evaluated by the National Institute for Health and Care Excellence (NICE) to decide if the treatment represents good value for the NHS. Patient access scheme (PAS) allows manufacturers to subsidise the cost of medicines used by the NHS through agreements with pharmaceutical companies.
Patient access schemes can sometimes incorporate products with a homecare service within a PAS. Where a pharma funded homecare service is offered, the homecare provider is appointed by the pharma company. Trusts will be responsible for ensuring they use a compliant route to market for these services and ensure that all homecare services, including pharma funded, are defined under a service level agreement.
For information on the LPP PAS project click here
1Patient access schemes liaison Unit – NICE (2019)
This site is currently under construction. If you find a broken link or an issue with the page then please contact firstname.lastname@example.org